Compare Citius Pharmaceuticals Inc (CTXR) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Plug Power Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Plug Power Inc trades at $1.73 (market cap $2.42B). The key difference: Plug Power Inc is far larger — about 177.7× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 53,851,702). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Plug Power Inc for 41 Days on average.
| CTXR | PLUG | |
|---|---|---|
Market Cap | $13.62M | $2.42B |
Volume | 132,438 | 53,851,702 |
Sector | Health | Industrials |
52-Week High | $1.82 | $4.14 |
52-Week Low | $0.48 | $1.73 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $3.79M | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Plug Power (PLUG) trades at $1.78, down 4.3% today, reflecting ongoing operational challenges despite recent strategic partnerships. The stock shows bearish technical signals with negative moving averages, while fundamentally the company continues to report significant losses with a -220.59% net income margin and negative cash flow. Recent news highlights a major 280 MW electrolyzer agreement with Arcadia eFuels and expansion in Australia/New Zealand, providing potential growth catalysts amid persistent financial headwinds.
The outlook remains challenging with substantial execution risks, though analyst consensus suggests 75% upside to the $3.13 price target. Key risks include continued cash burn, high debt levels, and competitive pressure in the hydrogen sector. Investment appeal depends on successful commercialization of green hydrogen projects and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
